Document:

Warrant Agreement, dated September 12, 2003

 Exhibit 10.60 
  
 Warrant Agreement 
  
 Warrant to Eli Lilly and Company for the Purchase of Shares of Common Stock of 
 Antares Pharma, Inc., 
 $.01 par value per Share 
  
 Between Antares Pharma, Inc. (the “Company”), a Minnesota
corporation, with its principal place of business at 707 Eagleview Boulevard, Suite 414, Exton, Pennsylvania 19341, and Eli Lilly and Company (“the Holder”), an Indiana corporation, with its principal place of business at Lilly Corporate
Center, Indianapolis, Indiana, 46285. 
  
 Whereas, the Company and
the Holder on this same date are entering into that certain License Agreement pursuant to which the Holder shall acquire certain rights to the Company’s needle free injection technology; and 
  
 Whereas, the License Agreement requires the Company to grant to the Holder
the right to acquire, under the terms and conditions set forth in this Warrant Agreement, shares of the Company’s common stock; and 
  
 Whereas, the exercise price of the warrants provided herein, subject to adjustment as provided herein, was determined by multiplying the average closing
price of Antares common stock over the last twenty trading days prior to the signing of the License Agreement by a factor of two; 
  
 Therefore, for good and valuable consideration, the sufficiency of which is hereby acknowledged by both parties, Antares and Lilly agree to the following
terms: 
  
 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE
UPON EXERCISE THEREOF MAY NOT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED UNLESS THERE
IS (i) AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT RELATED THERETO, OR (ii) AN OPINION OF COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED. 
  
 THIS Warrant Agreement CERTIFIES that, for value received, Holder is entitled to subscribe for and purchase from the Company, upon the terms and
conditions set forth herein, at any time or from time to time after the date hereof, and before 5:00 P.M. on September 12, 2013, Pennsylvania time (the “Exercise Period”), one million (1,000,000) shares of the Company’s Common Stock,
$.01 par value (“Common Stock”), at a price per share of $3.776 (the “Exercise Price”). This Warrant may be transferred in whole or in part without restriction. The term the “Holder” as used herein shall include any
transferee to whom this Warrant has been transferred in accordance with the above. The number of shares of Common Stock issuable upon exercise of the Warrants (the “Warrant 

 
Shares”) and the Exercise Price may be adjusted from time to time as hereinafter set forth. 
  
 1. Right to Exercise 
 This Warrant may be exercised by the Holder or its appropriate transferee during the Exercise Period, as to the whole or any lesser number of whole
Warrant Shares, by the surrender of this Warrant (with the election at the end hereof duly executed) to the Company at its office at 707 Eagleview Boulevard, Suite 414, Exton, Pennsylvania 19341, or at such other place as is designated in writing by
the Company, together with a certified or bank cashier’s check payable to the order of the Company in an amount equal to the Exercise Price multiplied by the number of Warrant Shares for which this Warrant is being exercised (the “Stock
Purchase Price”). 
  
 2. Conversion Right 

(a) In lieu of the payment of the Stock Purchase Price, the Holder shall have the right (but not the obligation), to require the Company to convert
this Warrant, in whole or in part, into shares of Common Stock (the “Conversion Right”) as provided for in this Section 2. Upon exercise of the Conversion Right, the Company shall deliver to the Holder (without payment by the Holder of any
of the Stock Purchase Price) that number of shares of Common Stock (the “Conversion Shares”) equal to the quotient obtained by dividing (x) the value of this Warrant (or portion thereof as to which the Conversion Right is being exercised
if the Conversion Right is being exercised in part) at the time the Conversion Right is exercised (determined by subtracting the aggregate Stock Purchase Price of the shares of Common Stock as to which the Conversion Right is being exercised in
effect immediately prior to the exercise of the Conversion Right from the aggregate Current Market Price (as defined in Section 6(b) hereof) of the shares of Common Stock as to which the Conversion Right is being exercised immediately prior to the
exercise of the Conversion Right) by (y) the Current Market Price of one share of Common Stock immediately prior to the exercise of the Conversion Right. 
  
 (b) The Conversion Rights provided under this Section 2 may be exercised in whole or in part and at any time and from time to time while any part of the
Warrants remain outstanding. In order to exercise the Conversion Right, the Holder shall surrender to the Company, at its offices, this Warrant with the Notice of Conversion at the end hereof duly executed. The presentation and surrender shall be
deemed a waiver by the Company of the Holder’s obligation to pay all or any portion of the aggregate purchase price payable for the shares of Common Stock as to which such Conversion Right is being exercised. This Warrant (or so much thereof as
shall have been surrendered for conversion) shall be deemed to have been converted immediately prior to the close of business on the day of surrender of such Warrant for conversion in accordance with the foregoing provisions. 
  
 3. Holder of Record and Partial Exercises 
 Upon each exercise of the Holder’s rights to purchase Warrant Shares or Conversion Shares, the Holder shall be deemed to be the holder of record of
the Warrant Shares or Conversion Shares issuable upon such exercise or conversion, notwithstanding that the 
  

 2 

 
transfer books of the Company shall then be closed or certificates representing such Warrant Shares or Conversion Shares shall not then have been actually
delivered to the Holder. As soon as practicable after each such exercise or conversion of this Warrant, the Company shall issue and deliver to the Holder a certificate or certificates for the Warrant Shares or Conversion Shares issuable upon such
exercise or conversion, registered in the name of the Holder or its designee. If this Warrant should be exercised or converted in part only, the Company shall, upon surrender of this Warrant for cancellation, execute and deliver a new Warrant
evidencing the right of the Holder to purchase the balance of the Warrant Shares (or portions thereof) or to convert the balance of the Conversion Shares in accordance with provisions of this Agreement. 
  
 4. Warrant Register and Transfers 
 The Company shall maintain books for the ownership, transfer and registration of the Warrant in a Warrant Register. Any future Warrants issued as a result
of the transfer or exercise or conversion in part of this Warrant shall be numbered and shall be registered in the Warrant Register as they are issued. The Company shall be entitled to treat the registered holder of any Warrant on the Warrant
Register as the owner in fact thereof for all purposes and shall not be bound to recognize any equitable or other claim to or interest in such Warrant on the part of any other person, and shall not be liable for any registration or transfer of
Warrants which are registered or to be registered in the name of a fiduciary or the nominee of a fiduciary unless made with the actual knowledge that a fiduciary or nominee is committing a breach of trust in requesting such registration or transfer,
or with the knowledge of such facts that its participation therein amounts to bad faith. This Warrant shall be transferable only on the books of the Company upon delivery thereof duly endorsed by the Holder or by the Holder’s duly authorized
attorney or representative, or accompanied by proper evidence of succession, assignment, or authority to transfer. Upon any registration of transfer, the Company shall deliver a new Warrant or Warrants to the person entitled thereto. Notwithstanding
the foregoing, the Company shall have no obligation to cause Warrants to be transferred on its books to any person unless and until the Holder delivers an opinion of Holder’s outside counsel that such transfer does comply with the provisions of
the Securities Act of 1933, as amended, and the rules and regulations thereunder. 
  
 5. Reservation of Authorized Shares 
 The Company shall at all times reserve and keep available out of
its authorized but unissued shares of Common Stock, solely for the purpose of providing for the exercise of the Warrants, such number of shares of Common Stock as shall from time to time equal the number of shares sufficient to permit the exercise
of the Warrants in accordance with their respective terms. The Company covenants that all shares of Common Stock issuable upon exercise of this Warrant, upon receipt by the Company of the full Exercise Price therefor, and all shares of Common Stock
issuable upon conversion of this Warrant, shall be validly issued, fully paid, and nonassessable, without any personal liability attaching to the ownership thereof, and will not be issued in violation of any preemptive rights of stockholders,
optionholders, warrantholders or any other persons and the Holder will receive good title to the securities purchased by it, free and clear of all liens, security 

  

 3 

 interests, pledges, charges, encumbrances, stockholders’ agreements and voting trusts which might be created by acts
or omissions to act of the Company. 
  
 6. Warrant Price
Computation Adjustments to the Number of Shares and the Exercise Price 
  
 (a) In case the Company shall at any time after the date the Warrants were first issued engage in any transaction, or act in any way, to affect the capital structure of the Company, including but not limited to the
following specific scenarios in subsections(a)(i)-(vii) below, (a “Capital Transaction”), wherein the Company: 
  
 (i) declares a dividend on the outstanding Common Stock payable in shares of its capital stock; 
 (ii) divides or subdivides the outstanding Common Stock; 
 (iii) combines the outstanding Common Stock into a smaller number of shares, or 
 (iv) issues any shares of
its capital stock by reclassification of the Common Stock (including any such reclassification in connection with a consolidation or merger in which the Company is the continuing corporation); 
 (v) exchanges Common Stock for the securities of a new entity pursuant to a consolidation or merger; or 
 (vi) issues debt instruments to holders of Common Stock generally; 
  
 then the Exercise Price shall be adjusted proportionately and the number and kind of securities issuable upon exercise or conversion of this
Warrant shall be adjusted proportionately so that the Holder after such Capital Transaction shall be entitled to receive the aggregate number, overall value and kind of shares which, if such Warrant had been exercised or converted immediately prior
to such time, the Holder would have owned upon such exercise or conversion and been entitled to receive by virtue of such Capital Transaction, all in accordance with the provisions of this Section 6. Such adjustment shall be made successively
whenever any Capital Transaction shall occur. 
  
 (b) For the
purpose of any computation under this Warrant, the Current Market Price per share of Common Stock on any date shall be deemed to be the average of the daily closing prices for the twenty (20) consecutive trading days immediately preceding the date
in question. The closing price for each day shall be the last reported sales price regular way or, in case no such reported sale takes place on such day, the closing bid price regular way, in either case on the principal national securities exchange
(including, for purposes hereof, the Nasdaq SmallCap Market) on which the Common Stock is listed or admitted to trading or, if the Common Stock is not listed or admitted to trading on any national securities exchange, the highest reported bid price
for the Common Stock as reported by a recognized interdealer quotation system or as furnished by the National Association of Securities Dealers, Inc. through Nasdaq or a similar organization if Nasdaq is no longer reporting such information. If on
any such date the Common Stock is not listed or admitted to trading on any national securities exchange and is not quoted by Nasdaq or any similar organization, the fair value of a share of Common Stock on such date, as determined in good faith by a
nationally recognized investment banking 

  

 4 

 
firm selected by mutual agreement of the parties, whose determination shall be conclusive absent manifest error, shall be used. 
  
 (c) No adjustment in the Exercise Price shall be required if such adjustment
is less than $.05; provided, however, that any adjustments which by reason of this Section 6 are not required to be made shall be carried forward and taken into account in any subsequent adjustment. All calculations under this Section 6 shall be
made to the nearest cent or to the nearest one-thousandth of a share, as the case may be. 
  
 (d) In any case in which this Section 6 shall require that an adjustment in the Exercise Price be made effective as of a record date for a specified event, the Company may elect to defer, until the occurrence of such
event and after such record date, issuing to the Holder, if the Holder exercised or converted this Warrant, those shares of Common Stock, if any, issuable upon such exercise or conversion over and above the shares of Common Stock, if any, issuable
upon such exercise or conversion on the basis of the Exercise Price in effect prior to such adjustment; provided, however, that in such case where the Company elects such a deferral the Company shall deliver to the Holder a due bill or other
appropriate instrument evidencing the Holder’s right to receive such additional shares upon the occurrence of the event requiring such adjustment.  
  

(e) Whenever there shall be an adjustment provided in this Section 6, the Company shall promptly cause written notice thereof to be sent by registered
mail or overnight courier, postage prepaid, to the Holder, at its address as it shall appear in the Warrant Register, which notice shall be accompanied by an officer’s certificate setting forth the number of Warrant Shares purchasable upon the
exercise of this Warrant and the Exercise Price after such adjustment and setting forth a brief statement of the facts requiring such adjustment and the computation thereof. 
  
 (f) The Company shall not be required to issue fractions of shares of Common Stock or other capital stock of the Company
upon the exercise or conversion of this Warrant. If any fraction of a share would be issuable on the exercise or conversion of this Warrant (or specified portions thereof), the Company shall purchase such fraction for an amount in cash equal to the
same fraction of the Current Market Price of such share of Common Stock on the date of exercise or conversion of this Warrant. 
  
 7. Merger 
 (a) In case of any
consolidation with or merger of the Company with or into another corporation (other than a merger or consolidation in which the Company is the surviving or continuing corporation), or in case of any sale, lease, or conveyance to another corporation
of all or substantially all of the property and assets of the Company, such successor, leasing, or purchasing corporation, as the case may be, shall (i) execute with the Holder an agreement providing that the Holder shall have the right thereafter
to receive upon exercise or conversion of this Warrant solely the kind and amount of shares of stock and other securities, property, cash, or any combination thereof receivable upon such consolidation, merger, sale, lease, or conveyance by a holder
of the number of shares of Common Stock for which this Warrant might have been exercised or converted 

  

 5 

 immediately prior to such consolidation, merger, sale, lease, or conveyance, and (ii) make effective provision in its
certificate of incorporation or otherwise, if necessary, to effect such agreement. Such agreement shall provide for adjustments which shall be as nearly equivalent as practicable to the adjustments in Section 6. 
  
 (b) The above provisions of this Section 7 shall similarly apply to
successive reclassifications and changes of shares of Common Stock and to successive consolidations, mergers, sales, leases, or conveyances. 
  
 8. Notice of Adjustments and Extraordinary Distributions to Shareholders 
  
 In case at any time the Company shall propose: 
  
 (i) to pay any dividend or make any distribution on shares of Common Stock in shares of Common Stock or make any other distribution to all holders of
Common Stock; or 
  
 (ii) to issue any rights, warrants, or other
securities to all holders of Common Stock entitling them to purchase any additional shares of Common Stock or any other rights, warrants, or other securities; or 
  
 (iii) to effect any Capital Transaction, including but not limited to reclassification or change of outstanding shares of
Common Stock, or any consolidation, merger, sale, lease, or conveyance of property, as described in Section 7; or 
  
 (iv) to effect any liquidation, dissolution, or winding-up of the Company; or. 
  
 (v) to take any other action which would cause an adjustment to the Exercise Price; 
  
 then, and in any one or more of such cases, the Company shall give written notice thereof, by
registered mail, postage prepaid, to the Holder at the Holder’s address as it shall appear in the Warrant Register, mailed at least 15 days prior to (i) the date as of which the holders of record of shares of Common Stock (to be entitled to
receive any such dividend, distribution, rights, warrants, or other securities) are to be determined, (ii) the date on which any such reclassification, change of outstanding shares of Common Stock, consolidation, merger, sale, lease, conveyance of
property, liquidation, dissolution, or winding-up is expected to become effective, and the date as of which it is expected that holders of record of shares of Common Stock shall be entitled to exchange their shares for securities or other property,
if any, deliverable upon such reclassification, change of outstanding shares, consolidation, merger, sale, lease, conveyance of property, liquidation, dissolution, or winding-up, or (iii) the date of such action which would require an adjustment to
the Exercise Price. 
  

 6 

 9. Payment of Taxes 
  
 The issuance of any shares or other securities upon the exercise or conversion of this Warrant, and the delivery of
certificates or other instruments representing such shares or other securities, shall be made without charge to the Holder for any tax or other charge in respect of such issuance. The Company shall not, however, be required to pay any tax which may
be payable in respect of any transfer involved in the issue and delivery of any certificate in a name other than that of the Holder and the Company shall not be required to issue or deliver any such certificate unless and until the person or persons
requesting the issue thereof shall have paid to the Company the amount of such tax or shall have established to the satisfaction of the Company that such tax has been paid. The Holder and/or its transferee shall be responsible for income taxes due
under federal, state or other law, if any such tax is due. 
  
 10.
Execution of Registration Rights Agreement 
  
 The Company
shall execute simultaneous with this Warrant Agreement a Registration Rights Agreement pursuant to which the Company shall register and maintain throughout the term of this Warrant Agreement a shelf registration for all shares of Common Stock
subject to the Warrant granted herein in accordance with the Securities Act of 1933. All expenses of such a registration shall be borne by the Company. 
  
 11. No Restrictions on Shares Subject to the Warrant 
  
 The Shares of Common Stock issued upon exercise of the Warrants shall not be subject to any contractual restrictions, and, once the shares issued pursuant
to exercise of the Warrant have been registered in accordance with the Registration Rights Agreement and the Securities Act of 1933, shall be freely transferable. 
  
 12. Loss or Mutilation of Warrant 
  
 Upon receipt of evidence satisfactory to the Company of the loss, theft, destruction, or mutilation of any Warrant (and upon
surrender of any Warrant if mutilated), and upon reimbursement of the Company’s reasonable incidental expenses, the Company shall execute and deliver to the Holder thereof a new Warrant of like date, tenor, and denomination. 
  
 13. Warrantholder Not a Shareholder Until Exercise 
  
 The Holder of any Warrant shall not have, solely on account of such status,
any rights of a shareholder of the Company, either at law or in equity, or to any notice of meetings of stockholders or of any other proceedings of the Company, except as provided in this Warrant Agreement. 
  
 14. Choice of Law and Forum Selection 
  
 This Warrant shall be construed in accordance with the laws of the State of
Deleware applicable to contracts made and performed within such State, without regard to principles of conflicts of law. 
  

 7 

 15. Waiver of Jury Trial 
  
 The Company and the Holder each hereby waives all right to trial by jury of any claim, action, proceeding or counterclaim
brought against the other party of any issue related to the subject matter of this Agreement, of any dispute that arises under or relates to this Agreement, or of any claim of injury or damage of any and every kind whatsoever by one party against
the other. 
  
 16. Injunctive Relief 
  
 The Company agrees that remedies at law of the Holder of this Warrant in the
event of any default or threatened default by the Company in the performance or compliance with any of the terms of this Warrant are not and will not be adequate and that such default or threatened default will result in irreparable harm to the
Holder, and that, to the fullest extent permitted by law, such terms may be specifically enforced by a decree for the specific performance of any provision of this Warrant Agreement or by an injunction against a violation of any of the terms hereof.
The provision of such equitable relief as contained in the first sentence of this Section is not intended by the parties to be the exclusive remedy for the Holder, and such other remedies, including legal remedies, as may be appropriate to the
situation, are and shall remain available to the Holder to pursue. 
  
 17. Financial Statements 
  
 If at anytime the
Company is not subject to the reporting requirements of the Securities Exchange Act of 1934, the Company shall provide to Lilly, not later than 30 days after the end of each quarter, unaudited quarterly financial statements, and within 90 days of
the end of each year, audited annual financial statements prepared in accordance with generally accepted accounting principles, consistently applied. 
  
 Dated as of: September 12, 2003 
  

	Antares Pharma, Inc.
		
	 By:
	 	 /s/    Roger Harrison        

	Name: Roger Harrison, Ph.D.
	 Title: President, Chief Executive Officer
         and Chairman of the Board of Directors

  

 8 

 FORM OF ASSIGNMENT 
  
 (To be executed by the registered holder if such holder desires to transfer the attached Warrant.) 
  
 FOR VALUE RECEIVED, Eli Lilly and Company hereby sells, assigns, and
transfers unto                          a Warrant to purchase         
shares of Common Stock, $.01 per share, of Antares, Inc. (the “Company”), together with all right, title, and interest therein, and does hereby irrevocably constitute and appoint
                 attorney to transfer such Warrant on the books of the Company, with full power of substitution. 
  
 Dated:
                                     
  
 Eli Lilly and Company 
  
 By:
                                        

 Name: 
 Its: 
  
 NOTICE 
  
 The signature on the foregoing Assignment must correspond to the name as written upon the face of this Warrant in every
particular, without alteration or enlargement or any change whatsoever. 
  
 To:
  Antares Pharma, Inc. 
 707 Eagleview Boulevard, Suite 414 
 Exton, PA19341 
  

 9 

 ELECTION TO EXERCISE 
  
 The undersigned hereby exercises his or its rights to purchase
             Warrant Shares covered by the within Warrant and tenders payment herewith in the amount of
$             in accordance with the terms thereof, and requests that certificates for such securities be issued in the name of, and delivered to: 
  
 (Print Name, Address and Social Security 
     or Tax Identification Number) 
  
 and, if such number of Warrant Shares shall not be all the Warrant Shares covered by the within Warrant, that a new Warrant for the balance of the Warrant Shares covered
by the within Warrant be registered in the name of, and delivered to, the undersigned at the address stated below. 
  

	Dated:                                     
                                        
                                 	 	 	 	 
			
	Name:
                                        
                                        
                             	 	 	 	  
	 (Print)
	 	 	 	 
	                                      
                                        
                                        
     	 	 	 	 
	 (Signature)
	 	 	 	 
	  
 Address:                                     
                                        
                             
	 	 	 	 
	 	 	 	 	 
	                                      
                                        
                                        
     	 	 	 	  
	 	 	 	 	 

 To:   Antares Pharma, Inc. 
 707 Eagleview Boulevard, Suite 414 
 Exton, PA
19341 
  

 10 

 CASHLESS EXERCISE FORM 
  
 (To be executed upon conversion of the attached Warrant) 
  
 The undersigned hereby irrevocably elects to surrender its Warrant for the number of shares of Common Stock as shall be
issuable pursuant to the cashless exercise provisions of the within Warrant, in respect of              shares of Common Stock underlying the within Warrant, and requests that
certificates for such securities be issued in the name of, and delivered to: 
  
 (Print Name, Address and Social Security 
     or Tax Identification Number) 

 
 and, if such number of shares shall not be all the shares exchangeable or purchasable
under the within Warrant, that a new Warrant for the balance of the Warrant Shares covered by the within Warrant be registered in the name of, and delivered to, the undersigned at the address stated below. 
  

	Dated:                                     
                                        
                                 	 	 	 	 
			
	Name:
                                        
                                        
                             	 	 	 	  
	 (Print)
	 	 	 	 
	                                      
                                        
                                        
     	 	 	 	 
	 (Signature)
	 	 	 	 
	  
 Address:                                     
                                        
                             
	 	 	 	 
	 	 	 	 	 
	                                      
                                        
                                        
     	 	 	 	  
	 	 	 	 	 

  

 11Registration Rights Agreement, dated September 12, 2003

 Exhibit 10.61 
  
 REGISTRATION RIGHTS AGREEMENT 
  

This Registration Rights Agreement (the “Agreement”) is made and entered into as of this 12th day of September, 2003 by and among Antares Pharma, Inc. a Minnesota corporation (the “Company”), and Eli Lilly and Company, an Indiana corporation
(the “Holder”). 
  
 WHEREAS, the Company and the Holder
are entering into that certain License Agreement of even date herewith, pursuant to which the Company and the Holder will collaborate on the development of a needle-free injection device and the Holder will have marketing rights in the Territory to
such device, all as provided for in the License Agreement; and 
  
 WHEREAS, the Company and the Holder are also entering into a separate Warrant Agreement, of even date herewith, pursuant to which the Company is granting to the Holder a Warrant to acquire 1,000,000 shares of the Company’s common
stock, $.01 par value, at an exercise price of $3.776, exercisable over a ten (10) year period; and 
  
 WHEREAS, the Holder wishes to have the ability, upon exercise or conversion and/or thereafter, to register such shares for sale to members of the public;

  
 THEREFORE, the Company and the Holder hereby agree as follows:

  
 1. Certain Definitions. 
  
 Capitalized terms not otherwise defined herein shall have the meanings
ascribed thereto in the License Agreement. As used in this Agreement, the following terms shall have the following meanings: 
  
 “Affiliate” means, with respect to any person, any other person which directly or indirectly controls, is controlled by, or is under common
control with, such person. 
  
 “Availability Date” has
the meaning as set forth in Section 3(k) of this Registration Rights Agreement. 
  
 “Business Day” means a day, other than a Saturday or Sunday, on which banks in New York City are open for the general transaction of business. 
  
 “Common Stock” shall mean the Company’s common stock, par value $0.01 per share, and any securities into
which such shares may hereinafter be reclassified. 
  
 “Demand Date” shall mean the date on which the Holder makes a demand on the Company pursuant to Sections 2(a) or 2(b) of this Registration Rights Agreement to cause the designated Registrable Securities to be registered in
accordance with the provisions contained herein. 

 “Filing Deadline” shall mean the date that falls forty-five (45) days after the Demand Date.

  
 “Prospectus” shall mean the prospectus included in
any Registration Statement, as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by such Registration Statement and by all other amendments and
supplements to the prospectus, including post-effective amendments and all material incorporated by reference in such prospectus. 
  
 “Register,” “registered” and “registration” refer to a registration made by preparing and filing a Registration Statement or
similar document in compliance with the 1933 Act (as defined below), and the declaration or ordering of effectiveness of such Registration Statement or document. 
  
 “Registrable Securities” shall mean (i) the Warrant Shares; and (ii) all additional shares issued or issuable to
the Holder pursuant to the terms of the Warrant Agreement with respect to, or in exchange for, the Warrant Shares or other Registrable Securities. 
  
 “Registration Statement” shall mean any registration statement of the Company filed under the 1933 Act or under the “blue sky” laws of
the appropriate state jurisdictions, as applicable, that covers the resale of any of the Registrable Securities pursuant to the provisions of this Agreement, amendments and supplements to such Registration Statement, including post-effective
amendments, all exhibits and all material incorporated by reference in such Registration Statement. 
  
 “SEC” means the U.S. Securities and Exchange Commission. 
  
 “1933 Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

  
 “1934 Act” means the Securities Exchange Act of
1934, as amended, and the rules and regulations promulgated thereunder. 
  
 “Warrants” means warrants to purchase shares of Common Stock issued to the Holder pursuant to the Warrant Agreement. 
  
 “Warrant Shares” means the shares of Common Stock issuable upon the exercise or conversion of the Warrants pursuant to the terms of the Warrant
Agreement. 
  
 2. Registration. 
  
 (a) Ordinary Demand. 
  
 The Holder shall be entitled, at any time and from time to time, to make a
written demand that the Company prepare and file with the SEC one Registration 
  

 2 

 Statement on Form S-3 (or, if Form S-3 is not then available to the Company, on such form of registration statement as is
then available to effect a registration for resale of the Registrable Securities), covering the resale of some or all of the Registrable Securities, and the Company shall, as soon as possible, but in any event no later than the Filing Deadline, file
said Registration Statement with the SEC. The Holder shall specify the number and type (if applicable) of Registrable Securities that it wishes to have registered, and note any jurisdictions in which it wishes to sell or offer to sell the
Registrable Securities for purposes of determining “blue sky” compliance. The Company shall have no obligation to file a registration statement pursuant to this section of the Registration Rights Agreement more than two times (2) per
calendar year, but in no event will Lilly be entitled to more than 10 registrations per this section during the term of the Agreement. . The Company shall use its reasonable best efforts to obtain from each person who has piggyback registration
rights a waiver of those rights with respect to a Registration Statement filed pursuant to this section.  
  
 The Company shall provide a copy of the proposed Registration Statement to the Holder at least five (5) Business Days before the date on which the Company
files the Registration Statement, and the Holder shall have the right to cause the Company to revise solely such portions of the Registration Statement as discuss the Holder, and the Holder shall in no way have the right to revise any other portions
of the Registration Statement.  
  
 The Company will use
its reasonable best efforts to cause the shares that are the subject of the demand to be registered and thereafter to maintain an effective registration. 
  
 (b) Anticipatory Demand 
 The Holder
shall be entitled, at any time and from time to time, to make a written demand that the Company prepare and file with the SEC a Registration Statement on Form S-3 (or, if Form S-3 is not then available to the Company, on such form of registration
statement as is then available to effect a registration for resale of the Registrable Securities), in anticipation of the exercise or conversion of some or all of the Warrants, covering the issuance to the Holder of some or all of the Registrable
Securities, and the Company shall, as soon as possible, but in any event no later than the Filing Deadline, file said Registration Statement with the SEC. The Holder shall specify the number and type (if applicable) of Registrable Securities that it
intends to have issued to it by the Company upon exercise or conversion (and the date on which it intends to so exercise or convert all or part of the Warrant) and the number and type (if applicable) of Registrable Securities that it wishes for the
Company to have registered, and the Holder shall note any jurisdictions in which it may wish to sell or offer to sell the Registrable Securities for purposes of determining “blue sky” compliance. The Company shall have no obligation to
file such an anticipatory registration statement pursuant to this Registration Rights Agreement more than two (2) times per calendar year; but in no event will Lilly be entitled to more than 10 registrations per the provisions of this Section during
the term of the Agreement. The Company shall use its reasonable best efforts to obtain from each person who has piggyback registration rights a waiver of those rights with respect to such Registration Statement.  
  

 3 

 The Company shall provide a copy of the proposed Registration Statement to the Holder at least five days
before the date on which the Company intends to and does in fact file the Registration Statement, and the Holder shall have the right to cause the Company to revise solely such portions of the Registration Statement as discuss the Holder, and the
Holder shall in no way have the right to revise any other portions of the Registration Statement.  
  
 The Company will use its reasonable best efforts to cause the shares that are the subject of the demand to be registered and thereafter to maintain an
effective registration 
  
 (c) Blue Sky Registration or
Exemption 
  
 Upon receipt of a demand as set forth in
Section 2(a) or Section 2(b), the Company shall use its reasonable best efforts to file the Registration Statement or otherwise to register the designated Registrable Securities, or to qualify the Registrable Securities for exemption, under the
“blue sky” laws of all relevant jurisdictions in which the Registrable Securities will or may be sold within the Filing Deadline. 
  
 (d) Expenses. 
  
 The Company will pay all expenses associated with each registration, including filing and printing fees, counsel and accounting fees and expenses, costs
associated with clearing the Registrable Securities for sale under applicable federal and state securities laws and listing fees, but excluding the fees and disbursements of more than one law firm serving as counsel to the Holder and discounts,
commissions, fees of underwriters, selling brokers, dealer managers or similar securities industry professionals with respect to the Registrable Securities being sold. 
  
 (e) Effectiveness. 
  
 (i) The Company shall use its reasonable best efforts to have the Registration Statement declared effective by the SEC and by applicable state authorities
as soon as possible, but in any event not later than the earlier to occur of (y) 120 days after the date of filing of such Registration Statement, or (z) five (5) Business Days following the Company’s receipt of a no-review letter from the SEC
and/or the applicable state authorities relating to the Registration Statement, as applicable; provided, however, if the Registration Statement is not declared effective within the time period set forth above, the Company shall continue to use its
reasonable best efforts to have the Registration Statement declared effective as soon as possible thereafter. 
  
 (ii) For not more than fifteen (15) consecutive days or for a total of not more than thirty (30) days in any twelve (12) month period, the Company may
delay the disclosure of material non-public information concerning the Company by terminating or suspending effectiveness of any registration contemplated by this Section 2 containing such information, the disclosure of which at the time is not, in
the good faith opinion of the Company, in the best interests of the Company (an “Allowed Delay”); provided, that the Company shall promptly (a) notify the Holder in writing of the existence of material 
  

 4 

 
non-public information giving rise to an Allowed Delay, and (b) advise the Holder in writing to cease all sales under the Registration Statement until the
end of the Allowed Delay. 
  
 (f) Underwritten Offering.

  
 If any offering pursuant to a Registration Statement filed
pursuant to Section 2(a) or Section 2(b) hereof involves an underwritten offering, the Holder shall have the right to select an investment banker and manager to administer the offering, which investment banker or manager shall be reasonably
satisfactory to the Company. 
  
 (g) Piggyback Rights

  
 If at any time prior to the expiration of the Registration
Period (as hereinafter defined) the Company shall determine to file with the SEC a Registration Statement relating to an offering for its own account or the account of others under the 1933 Act of any of its equity securities (other than on Form S-4
or Form S-8 or their then equivalents relating to equity securities to be issued solely in connection with any acquisition of any entity or business or equity securities issuable in connection with stock option or other employee benefit plans), the
Company shall send to the Holder written notice of such determination and, if within fifteen (15) days after the date of such notice, the Holder shall so request in writing, the Company shall include in such Registration Statement all or any part of
the Registrable Securities that the Holder requests to be registered, except that if, in connection with any underwritten public offering for the account of the Company the managing underwriter(s) thereof shall impose a limitation on the number of
shares of Common Stock which may be included in the Registration Statement because, in such underwriter(s)’ judgment, marketing or other factors dictate such limitation is necessary to facilitate public distribution, then the Company shall be
obligated to include in such Registration Statement only such limited portion of the Registrable Securities with respect to which the Holder has requested inclusion hereunder as the underwriter shall permit. The Company shall not exclude any of the
Holder’s Registrable Securities unless the Company has first excluded all outstanding securities, the holders of which are not entitled to inclusion of such securities in such Registration Statement or are not entitled to pro rata inclusion
with the Registrable Securities; and provided, however, that, after giving effect to the immediately preceding sentence, any exclusion of Registrable Securities shall be made pro rata with holders of other securities having the right to include such
securities in the Registration Statement other than holders of securities entitled to inclusion of their securities in such Registration Statement by reason of demand registration rights. No right to registration of Registrable Securities under this
Section 2(d) shall be construed to limit the number of or the right to demand any registration required under Section 2(a) or 2(b) hereof. If an offering in connection with which the Holder is entitled to registration under this Section 2(g) is an
underwritten offering, then each investor whose Registrable Securities are included in such Registration Statement shall, unless otherwise agreed by the Company, offer and sell such Registrable Securities in an underwritten offering using the same
underwriter or underwriters and, subject to the provisions of this Agreement, on the same terms and conditions as other shares of Common Stock included in such underwritten offering. 
  

 5 

 3. Company Obligations. 
  
 The Company will use its reasonable best efforts to effect the registration of the Registrable Securities in accordance with
the terms hereof, and pursuant thereto the Company will, as expeditiously as possible: 
  
 (a) use its reasonable best efforts to cause such Registration Statement to become effective and to remain continuously effective for a period that will terminate upon the date on which all Registrable Securities,
covered by such Registration Statement, as amended from time to time, have been sold; 
  
 (b) use its reasonable best efforts to prepare and file with the SEC such amendments and post-effective amendments to the Registration Statement and the Prospectus as may be necessary to keep the Registration
Statement effective for the period specified in Section 3(a) and to comply with the provisions of the 1933 Act and the 1934 Act with respect to the distribution of all Registrable Securities, provided however that the Company shall provide to the
Holder for review and revision all such Registration Statements no later than five Business Days before filing for the Holder to revise solely those sections of the Registration Statement that discuss the Holder; 
  
 (c) furnish to the Holder and their legal counsel (i) promptly after the same
is prepared and publicly distributed, filed with the SEC, or received by the Company (but not later than two (2) Business Days after the filing date, receipt date or sending date, as the case may be), at least five (5) copies of any Registration
Statement and any amendment thereto, each preliminary prospectus and Prospectus and each amendment or supplement thereto, and each letter written by or on behalf of the Company to the SEC or the staff of the SEC, and each item of correspondence from
the SEC or the staff of the SEC, in each case relating to such Registration Statement (other than any portion thereof which contains information for which the Company has sought confidential treatment), and (ii) such number of copies of a
Prospectus, including a preliminary prospectus, and all amendments and supplements thereto and such other documents as the Holder may reasonably request in order to facilitate the disposition of the Registrable Securities owned by the Holder;

  
 (d) in the event the Holder selects an underwriter for an
offering, the Company shall enter into and perform its reasonable obligations under an underwriting agreement, in usual and customary form, including, without limitation, customary indemnification and contribution obligations, with the underwriter
of such offering; 
  
 (e) if required by the underwriter, the
Company shall furnish, on the effective date of the Registration Statement (i) an opinion, dated as of such date, from independent legal counsel representing the Company for purposes of such Registration Statement, in form, scope and substance as is
customarily given in an underwritten public offering, addressed to the underwriter and (ii) a letter, dated such date, from the Company’s independent certified public accountants in form and substance as is customarily given by 
  

 6 

 independent certified public accountants to underwriters in an underwritten public offering, addressed to the underwriter
and the Holder; 
  
 (f) use its reasonable best efforts to prevent
the issuance of any stop order or other suspension of effectiveness and, if such order is issued, use its reasonable best efforts to obtain the withdrawal of any such order at the earliest possible moment; 
  
 (g) prior to any public offering of Registrable Securities, use its
reasonable best efforts to register or qualify or cooperate with the Holder and their counsel in connection with the registration or qualification of such Registrable Securities for offer and sale under the securities or blue sky laws of such
jurisdictions reasonably requested by the Holder and do any and all other reasonable acts or things necessary or advisable to enable the distribution in such jurisdictions of the Registrable Securities covered by the Registration Statement;

  
 (h) use its reasonable best efforts to cause all Registrable
Securities covered by a Registration Statement to be listed on each securities exchange, interdealer quotation system or other market on which similar securities issued by the Company are then listed; 
  
 (i) immediately notify the Holder, at any time when a Prospectus relating to
the Registrable Securities is required to be delivered under the 1933 Act, upon discovery that, or upon the happening of any event as a result of which, the Prospectus included in such Registration Statement, as then in effect, includes an untrue
statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing, and at the request of the Holder, promptly prepare
and furnish to the Holder a reasonable number of copies of a supplement to or an amendment of such Prospectus as may be necessary so that, as thereafter delivered to the purchasers of such Registrable Securities, such Prospectus shall not include an
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing; and 
  
 (j) otherwise use its reasonable best efforts to comply with all applicable
rules and regulations of the SEC under the 1933 Act and the 1934 Act and take such other actions as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder; and make available to its security holders, as
soon as reasonably practicable, but not later than the Availability Date (as defined below), an earnings statement covering a period of at least twelve (12) months, beginning after the effective date of each Registration Statement, which earnings
statement shall satisfy the provisions of Section 11(a) of the 1933 Act (for the purpose of this subsection 3(k), “Availability Date” means the 45th day following the end of the fourth fiscal quarter that includes the effective date of
such Registration Statement, except that, if such fourth fiscal quarter is the last quarter of the Company’s fiscal year, “Availability Date” means the 90th day after the end of such fourth fiscal quarter). 
  

 7 

 4. Due Diligence Review; Information. 
  
 The Company shall make available, during normal business hours, for
inspection and review by the Holder, advisors to and representatives of the Holder (who may or may not be affiliated with the Holder), and any underwriter participating in any disposition of Common Stock on behalf of the Holder pursuant to a
Registration Statement or amendments or supplements thereto or any blue sky, NASD or other filing, all financial and other records, all filings with the SEC, and all other corporate documents and properties of the Company as may be reasonably
necessary for the purpose of such review, and cause the Company’s officers, directors and employees, within a reasonable time period, to supply all such information reasonably requested by the Holder or any such representative, advisor or
underwriter in connection with such Registration Statement (including, without limitation, in response to all questions and other inquiries reasonably made or submitted by any of them), prior to and from time to time after the filing and
effectiveness of the Registration Statement for the sole purpose of enabling the Holder and such representatives, advisors and underwriters and their respective accountants and attorneys to conduct initial and ongoing due diligence with respect to
the Company and the accuracy of such Registration Statement; provided, however, that to the extent review of such information set forth in this paragraph would require disclosure to Lilly of competitive information that Antares considers
confidential, then Lilly is entitled to designate a third party to review such information and Lilly would not in such circumstance have access to such information. 
  
 Notwithstanding the foregoing, or anything else in this Registration Rights Agreement, the Company shall not disclose
material nonpublic information to the Holder, or to advisors to or representatives of the Holder, unless prior to disclosure of such information the Company identifies such information as being material nonpublic information and provides the Holder,
such advisors and representatives with the opportunity to accept or refuse to accept such material nonpublic information for review. 
  
 5. Obligations of the Holder. 
  
 (a) The Holder shall furnish in writing to the Company such information regarding itself, the Registrable Securities held by it and the intended method of
disposition of the Registrable Securities held by it, as shall be reasonably required to effect the registration of such Registrable Securities and shall execute such documents in connection with such registration as the Company may reasonably
request. At least fifteen (15) Business Days prior to the first anticipated filing date of any applicable Registration Statement, the Company shall notify the Holder of the information the Company requires from the Holder. The Holder shall provide
such information to the Company at least five (5) Business Days prior to the first anticipated filing date of such Registration Statement. For purposes of the first sentence of this Section 3(a), the methods of distribution to be specified by the
Holder shall include, without limitation, the sale of the Registrable Securities through (i) options transactions relating to the Registrable Securities, whether such options are listed on an options exchange or otherwise, or (ii) short sales of the
Registrable Securities. The Registration Statement shall also provide that, for purposes of the distribution of the Registrable Securities, the Holder may (i) enter into hedging transactions with broker-dealers or other financial 

  

 8 

 institutions, which may in turn engage in short sales of the Registrable Securities and deliver the Registrable
Securities to close out their short positions or (ii) loan or pledge the Registrable Securities to broker-dealers or other financial institutions, which in turn may sell the Registrable Securities. 
  
 (b) The Holder, by its acceptance of the Registrable Securities, agrees to
cooperate with the Company as reasonably requested by the Company in connection with the preparation and filing of a Registration Statement hereunder, unless the Holder has notified the Company in writing of its election to exclude some or all of
its Registrable Securities from such Registration Statement. 
  
 (c) In the event the Company, at the request of the Holder, determines to engage the services of an underwriter to sell or facilitate the sale of the Holder’s Registrable Securities, the Holder agrees to enter into and perform its
obligations under an underwriting agreement, in usual and customary form, including, without limitation, customary indemnification and contribution obligations, with the managing underwriter of such offering and to take such other actions as are
reasonably required in order to expedite or facilitate the dispositions of the Registrable Securities. 
  
 (d) The Holder agrees that, upon receipt of any notice from the Company of the happening of any event rendering a Registration Statement no longer
effective, the Holder will immediately discontinue disposition of Registrable Securities pursuant to the Registration Statement covering such Registrable Securities, until the Holder’s receipt of the copies of the supplemented or amended
Prospectus filed with the SEC and declared effective and, if so directed by the Company, the Holder shall deliver to the Company (at the expense of the Company) or destroy (and deliver to the Company a certificate of destruction) all copies in the
Holder’s possession of the Prospectus covering the Registrable Securities current at the time of receipt of such notice. 
  
 6. Indemnification. 
  
 (a) Indemnification by the Company. 
  
 The Company will indemnify and hold harmless the Holder and its respective Affiliates, officers, directors, members, employees and agents, successors and
assigns, against any losses, claims, damages or liabilities, joint or several, to which such seller, officer, director, member, or controlling person may become subject under the 1933 Act or otherwise, insofar as such losses, claims, damages or
liabilities (or actions in respect thereof) arise out of or are based upon: (i) any untrue statement or alleged untrue statement of any material fact contained in any Registration Statement, any preliminary prospectus or final prospectus contained
therein, or any amendment or supplement thereof; (ii) any blue sky application or other document executed by the Company specifically for that purpose or based upon written information furnished by the Company filed in any state or other
jurisdiction in order to qualify any or all of the Registrable Securities under the securities laws thereof; (iii) the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements
therein not misleading; (iv) any violation by the Company or its agents of any rule or regulation promulgated under the 1933 Act or the 1934 Act or any state securities law 
  

 9 

 
applicable to the Company or its agents and relating to action or inaction required of the Company in connection with this Agreement or with the registration
of the Registrable Securities as set forth herein; provided, however, that the Company will not be liable in any such case if and to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or
alleged untrue statement or omission or alleged omission so made in conformity with information furnished in writing by the Holder or any such controlling person specifically for use in such Registration Statement or Prospectus. 
  
 (b) Indemnification by the Holder. 
  
 In connection with any registration pursuant to the terms of this Agreement,
the Holder will furnish to the Company in writing such information as the Company reasonably requests concerning the Holder or the proposed manner of the Holder’s distribution for use in connection with any Registration Statement or Prospectus
and agrees, severally but not jointly, to indemnify and hold harmless, to the fullest extent permitted by law, the Company, its Subsidiaries and its and their respective directors, officers, employees, shareholders and each person who controls the
Company (within the meaning of the 1933 Act) against any losses, claims, damages, liabilities and expenses (including reasonable attorney fees) resulting from any untrue statement of a material fact or any omission of a material fact required to be
stated in the Registration Statement or prospectus or preliminary prospectus or amendment or supplement thereto or necessary to make the statements therein not misleading, to the extent, but only to the extent, that such untrue statement or omission
is contained in any information furnished in writing by the Holder to the Company specifically for inclusion in such Registration Statement or Prospectus or amendment or supplement thereto. In no event shall the liability of the Holder be greater in
amount than the aggregate dollar amount of the proceeds (net of all expenses paid by the Holder and the amount of any damages the Holder has otherwise been required to pay by reason of such untrue statement or omission) received by the Holder upon
the sale of the Registrable Securities included in the Registration Statement giving rise to such indemnification obligation. 
  
 (c) Conduct of Indemnification Proceedings. 
  
 Any person entitled to indemnification hereunder shall (i) give prompt notice to the indemnifying party of any claim with respect to which it seeks
indemnification and (ii) permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party; provided that any person entitled to indemnification hereunder shall have the right to employ
separate counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of such person unless (a) the indemnifying party has agreed to pay such fees or expenses, or (b) the indemnifying
party shall have failed to assume the defense of such claim and employ counsel reasonably satisfactory to such person or (c) in the reasonable judgment of any such person, based upon advice of its counsel, a conflict of interest exists between such
person and the indemnifying party with respect to such claims (in which case, if the person notifies the indemnifying party in writing that such person elects to employ separate counsel at the expense of the indemnifying party, the indemnifying
party shall not have the right to assume the defense of such claim on behalf 
  

 10 

 of such person); and provided, further, that the failure of any indemnified party to give notice as provided herein shall
not relieve the indemnifying party of its obligations hereunder, except to the extent that such failure to give notice shall materially adversely affect the indemnifying party in the defense of any such claim or litigation. It is understood that the
indemnifying party shall not, in connection with any proceeding in the same jurisdiction, be liable for fees or expenses of more than one separate firm of attorneys at any time for all such indemnified parties. No indemnifying party will, except
with the consent of the indemnified party, consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all
liability in respect of such claim or litigation. 
  
 (d)
Contribution. If for any reason the indemnification provided for in the preceding paragraphs (a) and (b) is unavailable to an indemnified party or insufficient to hold it harmless, other than as expressly specified therein, then the
indemnifying party shall contribute to the amount paid or payable by the indemnified party as a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect the relative fault of the indemnified party and the
indemnifying party, as well as any other relevant equitable considerations. No person guilty of fraudulent misrepresentation within the meaning of Section 11(f) of the 1933 Act shall be entitled to contribution from any person not guilty of such
fraudulent misrepresentation. In no event shall the contribution obligation by the Holder be greater in amount than the aggregate dollar amount of the proceeds (net of all expenses paid by such holder and the amount of any damages the Holder has
otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission) received by it upon the sale of the Registrable Securities giving rise to such contribution obligation. 
  
 7. Miscellaneous. 
  
 (a) Amendments and Waivers. This Agreement may be amended only by a
writing signed by the parties hereto. The Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company shall have obtained the written consent to such amendment, action or
omission to act, from the Holder. 
  
 (b) Notices. All
notices and other communications provided for or permitted hereunder shall be made as set forth in Section 20.5 of the License Agreement. 
  
 (c) Assignments and Transfers by the Holder. The provisions of this Agreement shall be binding upon and inure to the benefit of the Holder and its
permitted respective successors and assigns. The Holder may transfer or assign, in whole or from time to time in part, to one or more persons, its rights hereunder in connection with the transfer of Registrable Securities by the Holder to such
person or persons, provided that the Holder complies with all applicable laws thereto and provides written notice of assignment to the Company promptly after such assignment is effected. 
  

 11 

 (d) Assignments and Transfers by the Company. This Agreement may not be assigned by the Company
without the prior written consent of the Holder. 
  
 (e)
Benefits of the Agreement. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective permitted successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended
to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 
  
 (f) Counterparts; Faxes. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may also be executed via facsimile, which shall be deemed an original. 
  
 (g) Titles and Subtitles. The titles and subtitles used in this
Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 
  
 (h) Severability. Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be
ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be interpreted as if it were written so as to be enforceable to the maximum extent permitted by applicable law, and any
such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. To the extent permitted by applicable law, the parties hereby waive any provision of law which renders
any provisions hereof prohibited or unenforceable in any respect. 
  
 (i) Further Assurances. The parties shall execute and deliver all such further instruments and documents and take all such other actions as may reasonably be required to carry out the transactions contemplated hereby and to evidence
the fulfillment of the agreements herein contained. 
  
 (j)
Entire Agreement. This Agreement is intended by the parties as a final expression of their agreement and intended to be a complete and exclusive statement of the agreement and understanding of the parties hereto in respect of the subject
matter contained herein. This Agreement supersedes all prior agreements and understandings between the parties with respect to such subject matter. 
  
 (k) Applicable Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware without regard to
principles of conflicts of law. 
  
 (l) Jury Trial Waiver.
The Company and the Holder each hereby waives all right to trial by jury of any claim, action, proceeding or counterclaim brought against the 
  

 12 

 other party of any issue related to the subject matter of this Registration Rights Agreement, of any dispute that arises
under or relates to this Registration Rights Agreement, or of any claim of injury or damage of any and every kind whatsoever by one party against the other. 
  
 (m) Injunctive Relief. The Company agrees that remedies at law to the Holder in the event of any default or threatened default by the Company in
the performance or compliance with any of the terms of this Registration Rights Agreement are not and will not be adequate and that such default or threatened default will result in irreparable harm to the Holder, and that, to the fullest extent
permitted by law, such terms may be specifically enforced by a decree for the specific performance of any provision of this Registration Rights Agreement or by an injunction against a violation of any of the terms hereof. The provision of such
equitable relief as contained in the first sentence of this section is not intended by the parties to be the exclusive remedy for the Holder, and such other remedies, including legal remedies, as may be appropriate to the situation, are and shall
remain available to the Holder to pursue. 
  
 IN WITNESS WHEREOF,
the parties have executed this Agreement or caused their duly authorized officers to execute this Agreement as of the date first above written. 
  

	The Company:	 	 	 	ANTARES PHARMA, INC.
			
	 	 	By:	 	 /s/ Roger G. Harrison

	 	 	 	 	Name: Roger G. Harrison
	 	 	 	 	Title: Chief Executive Officer
			
	The Holder:	 	 	 	Eli Lilly and Company
			
	 	 	By:	 	 /s/ John C. Lechleiter

	 	 	 	 	Name: John C. Lechleiter
	 	 	 	 	Title: Executive Vice President

  

 13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}]]